Murine sex-limited protein (Sip) is an isotype of murine complement component C4 that shares 95% sequence identity with C4 as well as the intramolecular thioester necessary for C4 function but has no complement activity. SIp is nonfunctional at least in part because it is not cleaved by the activated form of complement protease Cls (Cls), which proteolytically activates C4 in the classical complement pathway. Sip is also distinct from C4 in that its expression in some mouse strains is under testosterone control. In the present studies, we used site-directed mutagenesis of C4 and expression of the mutant proteins in cultured cells to identify the amino acid substitutions in Sip that are responsible for resistance to Clis cleavage. We focused on sequence changes immediately downstream of the cleavage site in C4 because the arginine at that site is conserved in Sip, but the downstream sequences diverge substantially, with six differences in the first 7 residues followed by a 3-residue deletion in Sip. We found that a C4 mutant carrying only the 3-residue deletion is not cleaved by Cls and has essentially no hemolytic activity, whereas a mutant carrying only the six replacement changes is cleaved by Cli and has normal hemolytic activity. Both mutants have intact thioesters. A third mutant in which two acidic residues in the segment deleted in Sip were replaced by aliphatic residues is also cleaved by Cls, has an intact thioester group, and has normal hemolytic activity. These results indicate that the downstream mutations are responsible for the resistance of Sip to C s cleavage and suggest that the length rather than the specific sequence of this segment is critical in determining susceptibility to the protease.
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Twenty-six years ago, Shreffler and Owen (1) reported that mice have a serum protein present at distinctive levels among different inbred strains and that the genetic locus responsible for this quantitative trait is very closely linked to the genes for serologically defined murine histocompatibility (H-2) antigens. They named this then unidentified protein serum substance (Ss) and designated as S the H-2-linked genetic locus controlling the serum Ss level. This and subsequent studies (for review, see ref.
2) that mapped S between the K and D loci of H-2 provided conclusive evidence that the histocompatibility antigens are encoded in a gene complex rather than a single genetic locus.
In a later search for allotypic variants of Ss that was aimed at determining whether a regulatory gene controlling Ss expression or the Ss structural gene itself lay in the S locus, Passmore and Shreffler (3, 4) found a Ss variant that was expressed only in males of a subset of strains expressing high Ss levels. Because of its sex-limited expression, this Ss variant was named sex-limited protein (Slp) . More recent studies (for review, see refs. 2, 5, and 6) have established that Ss is murine complement component C4 and that Ss (C4) and Sip are isotypic rather than allotypic variants with distinct structural genes that lie closely linked within the S region of the H-2 complex.
The biological role of Sip is somewhat obscure. In addition to its sex-limited expression, it also appears to be totally absent in many mouse strains (3, 4) and may, therefore, be unessential. Furthermore, Ferreira et al. (7) have shown that Slp is devoid of C4 activity in spite of a primary structure that has been shown (8) (9) (10) (11) to be 95% identical to murine C4. Slp does, however, contain the internal thioester that is crucial to C4 function (12) , and it binds to sensitized erythrocytes under the same conditions that lead to C4 binding (5) . Most studies of Slp have, therefore, been aimed at identifying the structural difference(s) between C4 and Slp that renders Slp nonfunctional, at determining the biological function of this protein, and at understanding the biological significance and molecular mechanism of sex-limited expression. These are still essentially unresolved issues although recent sequence comparisons suggest that Slp has no biological function, as there appears to be little or no selective pressure to maintain a unique Slp amino acid sequence (13) . In addition, sequencing of a region several kilobases upstream of the Slp gene (14) suggests that testosterone regulation of Slp expression is due to a provirus inserted in this region.
The present studies were undertaken to identify the amino acid changes that render Slp nonfunctional. We have shown (15) that transfection of cultured mammalian cells with a mouse C4 cDNA under the transcriptional control of a simian virus 40 promoter results in the biosynthesis and secretion of mature active C4. In the present studies we have used site-directed mutagenesis of C4 to construct C4 mutants carrying Slp sequences. These mutants have been used to identify Slp sequences that render C4 inactive.
MATERIALS AND METHODS cDNAs. Construction of plasmid pC427A, which consists of a full-length mouse C4 cDNA cloned into the pcD expression vector (16) , and the sequence of the cDNA have been described (8) . All plasmid DNAs were prepared by a preparative alkaline lysis procedure (17) (excluding the CsC1 equilibrium centrifugation procedure) followed by extraction with phenol, treatment with RNase A at 50 ,ug/ml, precipitation twice from 5.5% (wt/vol) polyethylene glycol (PEG 6000) to remove RNA (18) Transient transfections were carried out as described (26, 27) by treating cells in 35-mm dishes with 2 ,ug of DNA in 0.7 ml of DEAE-dextran at 200 ,ug/ml followed by a 15% (vol/vol) glycerol shock after 6 (15, 30) . Immunoprecipitated products were fractionated on SDS/8.5% polyacrylamide gels, which were treated with EN3HANCE (DuPont/NEN) and autoradiographed. Tran- siently transfected COS cells were radiolabeled for 8 hr, 2 or 3 days after infection.
Autolytic cleavage of radiolabeled C4 and mutant C4 a-chains from COS-1 culture supernatants was carried out as described by Karp et al. (12) . Cleavage with CYF was carried out by adding human CrTs, prepared as described (31) , to culture supernatants to give a final concentration of 5 pug/ml and incubating at 370C for 2 hr. The reaction mixture was immunoprecipitated, separated on a SDS/polyacrylamide gel, and autoradiographed as described above.
C4 hemolytic activity was measured as described (15) Complement component C4 is a heterotrimer with a, f, and y subunits having-apparent molecular weights on SDS/ polyacrylamide gels of 94,000, 78,000, and 33,000, respectively. Slp is an essentially identical heterotrimer with subunit molecular weights of 104,000, 78,000, and 31,000; the a-chain difference between C4 and Slp is due primarily to additional glycosylation in Slp and the y-chain difference appears to be a gel artifact since both C4 and Slp -chains are identical in length with 98% amino acid sequence identity (8) (9) (10) (11) . Activation of C4 in the complement pathway involves cleavage of the a-chain to yield a small C4a peptide (Mr = 9000), which has weak anaphylatoxin activity, and activated C4b, which is composed of a'-(Mr 85,000), f-, and y-chains C4 is present in Slp (10, 11). However, the two sequences diverge substantially for about 10 residues immediately downstream of the cleavage site, including 6 amino acid changes and a deletion of 3 amino acids 7 residues from the cleavage site (Table 1) . This striking divergence between sequences that are 95% identical overall suggested that the amino acid changes result in a conformational change in Slp, at the cleavage site, that prevents Crs recognition or cleavage (35) . One of us later proposed (10) that the deletion is likely to be the most important barrier to Cri cleavage since the amino acid sequences of murine and human C4 also differ substantially in this region (except for the deletion) and both are cleaved by human Cri.
To test this proposal as well as the assumption that the mutations proximal to the cleavage site are indeed responsible for blocking Cri cleavage, we constructed two mutant mouse C4 cDNAs that would allow us to examine separately the effects of the deletion and the six amino acid replacements on C4 function. Only the deletion was introduced into the wild-type C4 sequence in the first mutant, designated CMD3; and only the replacements were introduced into the second, designated CM235 (see Table 1 ).
Plasmids carrying the mutant C4 sequences were transiently transfected into monkey COS-1 cells and mutant C4 proteins from cell culture supernatants were then tested for susceptibility to Crs cleavage and for the presence of the internal thioester by autolytic cleavage (12, 36) . The thioester is a sensitive indicator of the native structure (37) and hence we infer that mutant proteins that harbor the thioester have the native C4 conformation. Only the amino acid residues proximal to the CTs cleavage site (at the underlined arginine) are shown; these are residues 750-769 in the pre-pro-C4 sequence (8) . Flanking sequences are identical in C4 and Slp for over 100 residues in either direction except for an Asp --Glu substitution 7 residues downstream of the sequence shown. Dashes indicate identity with the wild-type C4w7 sequence and 0 denotes a deleted amino acid. *Ref. 34. tThree complete Slp cDNA sequences have been reported; two, designated Slpw7-l and Slpw7.2, are from distinct genes in mouse strain B10.WR (10, 13) and the third, Slp'F, is from mouse strain FM (11) . The proline at the N-terminal end of the segment shown for Slpw7.l is replaced by histidine in S1pW7.2 and SlpFM and hence is not distinctive of Slp. Fig. 1 is an autoradiogram of an SDS/polyacrylamide gel showing the results of Crs and autolytic cleavage of radiolabeled culture supernatants from COS-1 cells transiently transfected with plasmids pC427A, pCMD3, or pCM235, which encode wild-type, deleted, or substituted C4, respectively. These results show clearly that Crs does cleave the a-chain of mutant CM235 to yield an a'-chain but does not cleave the a-chain of CMD3. There is no evidence ofcleavage of CMD3 even after 6 hr in Crs at 10 ,&g/ml (data not shown). Hence the 3-amino acid deletion but not the 6-amino acid replacement is sufficient to block Crs cleavage. All three proteins show comparable autolytic cleavage patterns, indicating that both mutant proteins have overall conformations very similar to that of native C4; thus the effect of the mutation in CMD3 cannot be explained by a general deterioration of the native structure. Table 1 ). Lanes A fortuitous by-product of the construction of CMD3 was the related mutant CMD6 (Table 1) in which two charged glutamyl residues, in the segment deleted in Slp, are replaced by aliphatic leucyl and isoleucyl residues. Fig. 2 shows that this replacement mutant is also cleaved by CrTs and thus provides additional evidence that cr cleavage is not very dependent on the specific amino acid sequence of this region.
Although both CM235 and CMD6 are cleaved by CTs, they are somewhat less efficiently cleaved than wild-type C4. This is illustrated in the time dependence of the cleavage shown in Fig. 3 . For both mutants cleavage was complete after 3-6 hr in CT-at 10 ,g/ml (data not shown). Hence the changes in CM235 and CMD6 are not sufficient to block Crs cleavage, but they do result in poorer substrates for CFs.
Reversion of the Deletion Mutation Restores C4 Function. Close examination of Figs. 1 and 2 reveals that the a-chains of CMD3 and CMD6 have much greater mobilities relative to the wild-type C4w7 a-chain than would be expected from the anticipated mutations. These electrophoretic mobilities are consistent with CMD3 and CMD6 a-chains having a molecular weight of 91,000, suggestive of a loss of about 30 amino acid residues. The molecular change responsible for this increased mobility appears to lie in the N-terminal portion of the a'-chain since the aN autolytic fragments of both CMD3 and CMD6, and the a'-chain of CMD6 show a similar increase in mobility (Figs. 1-3) . Disproportionately large mobility shifts on SDS/polyacrylamide gels have been ob- and C4 mutant CMD6 from culture supernatants of COS-1 cells transiently transfected with plasmids pC427A and pCMD6 (see Table  1 ). Labels are as in Fig. 1 . The aN and a' bands from CMD6 appear slightly smaller at Mr 37,000 and 84,000, respectively.
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Samples were treated with Cls at 5 Ag/ml for 0, 0.5, 1, and 3 hr, immunoprecipitated, separated on an SDS/polyacrylamide gel, and autoradiographed. Other labels are as in Fig. 1. served, of course, in particular with the murine C4 P-and -chains (15) and with the a-chains of human C4A and C4B (34, 38) . Nevertheless, the large shift observed with CMD3 and CMD6 raised the possibility that other unanticipated changes in the cDNA sequence may have been introduced during the mutagenesis procedure. To eliminate this doubt, we used the same mutagenesis procedure to revert CMD3 back to the original wild-type C4w7 sequence by using oligonucleotide 236. The reverted sequence, in plasmid pRM236 directs the expression of a protein with an a-chain that is indistinguishable on SDS/polyacrylamide gels from that of wild-type C4 and is also indistinguishable from wild-type C4 in its reactivity with Crs and in autolysis (data not shown).
We conclude that the properties of CMD3, including the unexpectedly large shift in a-chain mobility are due only to the anticipated mutation and assume that this is the case with CMD6 as well.
Cls Cleavage Reflects Hemolytic Activity. Hemolytic activities of the mutant C4 proteins were assayed to determine the effects of each mutation on C4 functional activity. Stably transformed murine L cells were used for these studies because they express higher levels of C4 than transiently transfected COS-1 cells (15) . Cultures were radiolabeled with [35S]methionine and both C4 quantitation and hemolytic assays were carried out on the same sample of culture supernatant. Our results are given in Table 2 ; they demonstrate that mutants CM235 and CMD6 have approximately normal hemolytic activities whereas CMD3 has negligible activity. The small residual activity found with CMD3 is reproducible, suggesting that this mutant is cleaved by CT_ at a very slow rate. Although our studies were carried out with C4 rather than Slp, we infer that they apply to Slp. We cannot, of course, exclude the possibility that the 3-residue deletion has a very different effect within the context of the entire Slp sequence; but we feel this is quite unlikely. We also cannot exclude the more likely possibility of other structural defects in Slp that would render it inactive even if Cli cleavage were to occur. We have tried to address this question by placing into the pcD expression vector the wild-type Slp cDNA (10, 15 ) and a Slp mutant in which the three deleted residues have been restored (unpublished data). Expression of both wild-type and mutant Slp proteins is very poor, however (e.g., ref. 15) , and our preliminary results suggest that both proteins, from both COS-1 and L cells, are not in the native conformation because they do not appear to have intact internal thioester groups. These results are equivocal, however, because the levels of expression we observed were very low and C4 expression at similar low levels also yields apparently nonnative proteins (unpublished observations).
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